公开(公告)号：EP2419425A1

公开(公告)日：2012-02-22

申请号：EP10764741.4

申请日：2010-04-14

申请人： AstraZeneca AB

发明人： ARVIDSSON, Per, I ,  BURROWS, Jeremy, Nicholas ,  YNGVE, Ulrika ,  TJERNELD, Erica

IPC分类号： C07D413/14 ,  A61K31/5377 ,  A61P17/14 ,  A61P25/18 ,  A61P25/24 ,  A61P25/28 ,  A61P27/06 ,  A61P29/00 ,  A61P3/10 ,  A61P35/00

CPC分类号： C07D405/14 ,  A61K31/5377 ,  C07D413/14

摘要： The present invention relates to a new compound of formula (I) wherein R
1 is hydrogen or fluoro; R
2 and R
3 are independently selected from hydrogen or methyl; or a pharmaceutically acceptable salt thereof, pharmaceutical formulations containing said compound, to the use of said active compound in therapy, to the use for the treatment of conditions associated with glycogen synthase kinase-3 related disorders, such as Alzheimer's disease, as well as for the method of treatment of said disorders, comprising administering to a mammal, including human in need of such treatment, a therapeutically effective amount of said compound.

摘要翻译： 本发明涉及式（I）的新化合物，其中R 1是氢或氟; R 2和R 3独立地选自氢或甲基; 或其药学上可接受的盐，含有所述化合物的药物制剂，所述活性化合物在治疗中的用途，用于治疗与糖原合酶激酶-3相关病症如阿尔茨海默氏病有关的病症的用途，以及用于 治疗所述病症的方法包括给予需要这种治疗的哺乳动物包括人治疗有效量的所述化合物。

公开(公告)号：EP2142542A1

公开(公告)日：2010-01-13

申请号：EP08724302.8

申请日：2008-03-28

申请人： AstraZeneca AB

发明人： ARVIDSSON, Per ,  BURROWS, Jeremy ,  SÖDERMAN, Peter ,  YNGVE, Ulrika

IPC分类号： C07D471/04 ,  A61K31/437 ,  A61K31/5375 ,  A61P19/08 ,  A61P25/00 ,  A61P25/28 ,  A61P3/10

CPC分类号： C07D471/04

摘要： The present invention relates to new compounds of formula (I) as a free base or a pharmaceutically acceptable salt, solvate or solvate of salt thereof, a process for their preparation and new intermediates used therein, pharmaceutical formulations containing said therapeutically active compounds and to the use of said active compounds in therapy.

公开(公告)号：EP1890993A2

公开(公告)日：2008-02-27

申请号：EP06733399.7

申请日：2006-05-08

申请人： AstraZeneca AB

发明人： GYBÄCK, Helena ,  HAEBERLEIN, Markus ,  JONASSON, Catrin ,  KIHLSTRÖM, Jacob ,  MOLIN, Håkan ,  PLOBECK, Niklas ,  HETTMAN, Andreas ,  VIKLUND, Jenny ,  YNGVE, Ulrika ,  MOLIN, Berit

IPC分类号： C07C65/10 ,  A61K31/192 ,  A61P29/00 ,  C07C309/30 ,  C07C327/16 ,  C07C65/32

CPC分类号： C07C323/62 ,  C07C65/105 ,  C07C65/24 ,  C07C65/40 ,  C07C205/45 ,  C07C229/64 ,  C07C251/48 ,  C07C255/57 ,  C07C317/46 ,  C07C2601/14 ,  C07D213/32 ,  C07D213/34 ,  C07D213/55 ,  C07D213/70 ,  C07D215/14 ,  C07D217/16 ,  C07D241/42 ,  C07D271/06 ,  C07D277/36 ,  C07D277/64 ,  C07D295/155 ,  C07D307/80 ,  C07D309/04 ,  C07D333/60

摘要： Compounds of formula I, wherein Y = H, -OH, halo, -OC1-6alkyl, -C1-6alkyl, the two latter optionally substituted with halo, -CN, -OH, -CF3, -NH2; Rl = -C3-6cycloaUcyl, heterocycloalkyl, aryl, alkylaryl, heteroaryl, -C3-6-alkyl, optionally substituted with halo, -CN, -OH, -CF3, -OCF3, -NH2, -CONH2; M = -C(O)-, -C(H2)-, -CH(OR3)-, -N(Ra)-, -S(O)r-, heteroaryl and a bond; wherein Ra = H or C1-6alkyl and r = 0, 1 or 2; R2 = H, halo, -CN, or D = -C1-6alkyl, C3-6cycloalkyl, heterocycloalkyl, -N(CH3)2, aryl, alkylaryl, heteroaryl, and heterocyclic groups; where D is optionally substituted with G = halo, -NO2, -CN, -OH, -CF3, -OCF3, -NH2, -CONH2, -COOH, aryl, heteroaryl, heterocyclic groups, -C1-6alkyl, -C1-6alkoxy, heterocycloalkyl, and C1-6alkylcarboxylate; where D may be connected to G by L = -C(O)-, -S-, or -S(O2)-; and G may be further substituted with substituents selected from halo, -NO2, -CN, -OH, -CH3, -OCH3, -CF3, -OCF3, -NH2, -CONH2, -COOH, C1-6alkylcarboxylate; and R3 = -OH or C1-6alkoxy.

摘要翻译： 式I的化合物，其中R 1，Z，Y，M和R 2如说明书中所定义，其药学上可接受的盐，含有该化合物的药物组合物，其用于治疗目的的方法及其制备方法。